Top-line growth accelerated in Q1 driven by stockpiling across the portfolio, but the momentum should fade away in Q2. In the lockdown scenario, while demand for Vitamin D (Hidroferol) would continue to remain high, a significant decline in pollen allergies could weigh on Bilastine’s growth. Also, as Faes has opted out of the US due to the regulatory requirement of conducting (costly) clinical trials on Bilastine, we trim our estimates for the mid-term.
05 May 2020
Robust Q1; Bilastine’s US plan has taken a back seat
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust Q1; Bilastine’s US plan has taken a back seat
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
05 May 2020 -
Author:
Rishabh Kochar -
Pages:
3
Top-line growth accelerated in Q1 driven by stockpiling across the portfolio, but the momentum should fade away in Q2. In the lockdown scenario, while demand for Vitamin D (Hidroferol) would continue to remain high, a significant decline in pollen allergies could weigh on Bilastine’s growth. Also, as Faes has opted out of the US due to the regulatory requirement of conducting (costly) clinical trials on Bilastine, we trim our estimates for the mid-term.